Benchmark lowered the firm’s price target on Harvard Bioscience (HBIO) to $4.50 from $5.50 and keeps a Speculative Buy rating on the shares. End-user markets in biomedical research continue to be challenging for Harvard, says the analyst, who is lowering estimates as a result.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HBIO: